Premium
Cover Picture: The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor ( R )‐ S ‐Cyclopropyl‐ S ‐(4‐{[4‐{[(1 R ,2 R )‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer (ChemMedChem 7/2013)
Author(s) -
Lücking Ulrich,
Jautelat Rolf,
Krüger Martin,
Brumby Thomas,
Lienau Philip,
Schäfer Martina,
Briem Hans,
Schulze Julia,
Hillisch Alexander,
Reichel Andreas,
Wengner Antje Margret,
Siemeister Gerhard
Publication year - 2013
Publication title -
chemmedchem
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201390025
Subject(s) - cyclin dependent kinase , cdk inhibitor , trifluoromethyl , chemistry , cancer research , front cover , cyclin dependent kinase 6 , cell cycle , stereochemistry , cell , biochemistry , biology , cover (algebra) , organic chemistry , mechanical engineering , alkyl , engineering
The front cover picture shows the pan‐cyclin‐dependent kinase (CDK) inhibitor BAY 1000394 embedded in a schematic depiction of the cell cycle and a colored paraffin section of an untreated A2780Cis ovarian cancer tumor grown on a nude mouse. Aminopyrimdine BAY 1000394 is a balanced, orally available pan‐CDK inhibitor with potent, broad‐spectrum antiproliferative activity against human cancer cell lines, and is currently being investigated in a phase I clinical trial in patients with advanced solid tumors. For more details, see the Full Paper by Ulrich Lücking et al. on p. 1067 ff.